Heparin Global Market Report 2022| MENAFN.COM

Saturday, 01 October 2022 01:56 GMT

Heparin Global Market Report 2022

(MENAFN- GlobeNewsWire - Nasdaq)

New York, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report 'Heparin Global Market Report 2022' -
The global heparin market is expected to grow from $8.10 billion in 2021 to $8.64 billion in 2022 at a compound annual growth rate (CAGR) of 6.62%. The heparin market is expected to grow to $10.44 billion in 2026 at a compound annual growth rate (CAGR) of 4.86%.
The heparin market consists of sales of heparin by entities (organizations, partnerships, and sole proprietors) that refer to an anticoagulant (blood thinner) medication that prevents the formation of blood clots.It is injected into a vein to treat and prevent blood clots caused by certain medical conditions or procedures.
Heparin is widely used in hospitals to prevent excessive coagulation during cardiac surgery, extracorporeal circulation, or dialysis.
The main types of heparin include unfractionated heparin, low molecular weight heparin (LMWH), and ultra-low molecular weight heparin (ULMWH).The unfractionated heparin (UFH) market refers to a class of fast-acting anticoagulant medication that prevents clot formation by combining with antithrombin.
Unfractionated heparin binds to antithrombin and improves its ability to inhibit two of the body's most powerful clotting factors, factor Xa and factor IIa, in minutes. They are sourced from bovine or porcine and administered intravenous or subconscious. they are used in the treatment of venous thromboembolism, atrial fibrillation, renal impairment, coronary artery disease, and others. They are distributed through hospital pharmacies, drug stores or retail pharmacies, and online pharmacies.
North America was the largest region in the heparin market in 2021.Asia Pacific is expected to be the fastest-growing region in the forecast period.
The regions covered in the heparin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The heparin market research report is one of a series of new reports that provides heparin market statistics, including heparin industry global market size, regional shares, competitors with a heparin market share, detailed heparin market segments, market trends and opportunities, and any further data you may need to thrive in the heparin industry. This heparin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The increasing prevalence of chronic diseases is significantly driving the growth of the heparin market.Chronic diseases refer to medical conditions, which last more than one year and require constant medical attention or hospitalization for specialized treatment.
The changing lifestyle, eating habits, and inappropriate maintenance of body weight are the reasons for chronic conditions and a few more prolonged chronic infections lead to cancerous risk.Growing exposure to the disease has increased the demand for heparin, as they are widely used to make the blood thin during surgeries and various medical treatments.
For instance, according to a research report published in September 2020 by the American Action Forum, the prevalence and cost of chronic diseases in the US are growing and will continue to grow because of an increase in disease prevalence among children and young adults in addition to the aging of Baby Boomer (people born between 1946 and 1964) generation.Furthermore, according to the national public health agency of the US, the Centers for Disease Control and Prevention, 6 in 10 adults in the US have a chronic disease and 4 in 10 adults have two or more chronic diseases.
Therefore, the increasing prevalence of chronic diseases will drive the growth of the heparin market.
Product advancement is a key trend gaining popularity in the heparin market.Key players and their research wings are increasingly focusing on developing the advanced and improved heparin or heparin prefilled syringe with precision and convenience to increase their business reach and presence across the globe.
For instance, in April 2019, B.Braun, a Germany-based medical and pharmaceutical device company introduced the first FDA-approved Heparin Sodium Prefilled Syringe with an attached safety needle.
It is the first Heparin 5,000 USP Unit / 0.5 mL prefilled syringe with an attached safety needle for subcutaneous and intravenous use in the USA. It is preservative-free with 24-month stability at room temperature and upon activation, protects against accidental needle stick injuries.
In February 2020, Opocrin Spa, an Italy-based pharmaceutical company involved in the research, production, and marketing of active pharmaceutical ingredients acquired Laboratori Derivati Organici (LDO) for an undisclosed amount.This acquisition enables Opocrin to become the world's largest manufacturer of heparin and derivatives.
LDO is an Italian firm that specializes in the extraction of active pharmaceutical components from animal organs, with an emphasis on the production of heparin and its derivatives.
The countries covered in the heparin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA.
Read the full report:
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.